Effects of rosuvastatin on hsCRP in patients with acute coronary syndrome undergoing percutaneous coronary intervention

AIM: To study the effects of rosuvastain at different dosages on serum high-sensitivity C-reactive protein(hsCRP) in patients with acute coronary syndrome undergoing percutaneous coronary intervention(PCI).METHODS: Fifty-eight patients were randomly divided into two groups: experimental group was given rosuvastain 20 mg/day before PCI and 1 week after PCI and control group was given rosuvastain(10 mg/day) before and after PCI.Serum hsCRP at different time points(before PCI,1 day after PCI,1 week after PCI and 1 month after PCI) was detected.RESULTS: One day and one week after PCI,serum hsCRP level of patients in experimental group was significantly lower than that in control group(P<0.01) but no significant difference in serum hsCRP was seen at 1 month after PCI.CONCLUSION: Rosuvastain at the dosage of 20 mg/day before PCI and 1 week after PCI can better decrease the level of serum hsCRP than rosuvastain at the dosage of 10 mg/day in patients with acute coronary syndrome undergoing PCI.